
STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in…
STAT News publishes English-language reporting and analysis. Visit its official website for full articles and subscription information.
No recent stories in this category. Try All News or check back soon.

Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in…
PhRMA is suing the Trump administration, smaller biotech firms are frustrated…
Roche has inked a drug discovery deal with Chinese biotech Defand…
All six Nobel awardees in physiology or medicine, physics, and chemistry this year were men. Women make up…
Smaller biotech firms are trying to figure out how to win exemptions from Trump's import…
Power House health committees could get a lot of new members after the…
“A small, well-intended discount for safety net hospitals became a…
Eliminating hepatitis C is achievable — if the…
A startup didn't want to wait for doctors and…
There’s increasing evidence that older women with breast…
“Don’t google,” the pediatric geneticist warned. It took me five years to disobey.
About half of the patients in a study regained photosensitivity in their vision,…
The Trump administration has proposed a $70,000 fee for a popular work authorization program…
The brand drug industry’s main trade group is suing the Trump administration over…
In a setback for Merck, a Dutch court ordered a halt to the…
Forbion, a prominent European venture capital firm, said it has raised $2.6 billion, its largest…
In this edition of STAT's AIP Prognosis: Unresolved regulatory…
The World Health Organization released its first guidelines addressing the…
The Justice Department issued a new directive for combating fraud that noted the…
A new study found that visits by people born outside of the U.S.
Henri B. Kagan and Kenso Soai were awarded the 2026…


















